<DOC>
	<DOCNO>NCT00002203</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness take lamivudine ( 3TC ) plus zidovudine ( ZDV ) plus protease inhibitor ( PI ) take 3TC/ZDV combination tablet ( Combivir ) plus PI . This study also examine well patient follow dose schedule drug . Doctors believe take Combivir plus PI may effective take 3TC plus ZDV plus PI .</brief_summary>
	<brief_title>A Study Two Anti-HIV Drug Combinations</brief_title>
	<detailed_description>It hypothesize fixed-dose 3TC/ZDV tablet give bid combination protease inhibitor clinically equivalent effect plasma HIV-1 RNA level conventional regimen 3TC , ZDV , protease inhibitor . Patients stratify accord current protease inhibitor therapy randomize receive open-label therapy 1 Combivir tablet bid ( Arm II ) equivalent dose 3TC ZDV ( Arm I ) , plus current protease inhibitor 16 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV infection document license antibody ELISA assay confirm Western blot , positive HIV blood culture , positive HIV serum antigen , plasma viremia . CD4+ cell count least 300 cells/mm3 . HIV1 RNA le 10,000 copies/ml Roche Amplicor PCR assay . CDC Category A B Classification HIV infection ( clinical diagnosis AIDS ) . Compliance dose schedule protocol evaluation . Prior Medication : Required : 3TC 150 mg bid , ZDV 600 mg/day ( 200 mg tid 300 mg bid ) , plus marketed protease inhibitor ( ritonavir , saquinavir , indinavir , nelfinavir ) recommend dose least 10 week . Allowed : Inhaled corticosteroid treatment asthma . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Malabsorption syndrome affect drug absorption ( e.g. , Crohn 's disease chronic pancreatitis ) . Enrollment investigational protocol . Concurrent Medication : Excluded : Cytotoxic chemotherapeutic agent . Nonnucleoside reverse transcriptase inhibitor . Other investigational agent . Concurrent Treatment : Excluded : Radiation therapy . Prior Medication : Excluded : Cytotoxic chemotherapeutic immunomodulating agent systemic corticosteroid , IF2 , alphaIFN , betaIFN , gammaIFN ( except inhale corticosteroid treatment asthma ) within 4 week study entry . HIV immunotherapeutic vaccine within 3 month study entry . Prior Treatment : Excluded : Radiation therapy within 4 week study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1998</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>CD4-CD8 Ratio</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Patient Compliance</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>